trimetrexate has been researched along with Thrombopenia in 7 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Excerpt | Relevance | Reference |
|---|---|---|
| "If tumors are resistant to methotrexate because of decreased transport of drug (and also folate), then the same pharmacological principle used to develop TMTX/LV for the treatment of P." | 2.69 | High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection? ( Holcenberg, JS; Hum, M; Kamen, BA; Tkaczewski, I; Weaver, JW; Wilson, J, 1998) |
| " Thus, TMTX can be given with 5-FU (400 mg/m2) on a daily x 5-day bolus schedule at the 12 mg/m2 per day dose level, which was the recommended dose of TMTX as a single agent for phase II studies using the 5-day bolus schedule." | 1.28 | Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil. ( Catalano, R; Comis, RL; DeLap, RJ; Grillo-Lopez, AJ; Hudes, GR; LaCreta, F, 1989) |
| "Trimetrexate (TMTX) is a potent inhibitor of dihydrofolate reductase that circumvents the transport resistance seen with methotrexate and has a wide spectrum of preclinical activity." | 1.28 | A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion. ( Bishop, JF; Friedlander, ML; Morris, R; Olver, IN; Raghavan, D; Reece, P, 1989) |
| "Thrombocytopenia was dose limiting, but highly variable among patients at a given dose level; other toxicity was mild and uncommon." | 1.27 | Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. ( Cassidy, C; Chou, TC; Fanucchi, MP; Fleisher, M; Lokos, G; Niedzwiecki, D; Vidal, P; Walsh, TD; Williams, L; Young, CW, 1987) |
| " In early phase II testing, nine of 15 patients who experienced life-threatening or fatal toxic effects from trimetrexate had albumin levels less than or equal to 3." | 1.27 | Correlates of severe or life-threatening toxic effects from trimetrexate. ( Ellenberg, SS; Grem, JL; King, SA; Shoemaker, DD, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Witte, RS | 1 |
| Yeap, BY | 1 |
| Trump, DL | 1 |
| Pappo, AS | 1 |
| Vats, T | 1 |
| Williams, TE | 1 |
| Bernstein, M | 1 |
| Kamen, BA | 2 |
| Hum, M | 1 |
| Holcenberg, JS | 1 |
| Tkaczewski, I | 1 |
| Weaver, JW | 1 |
| Wilson, J | 1 |
| Hudes, GR | 1 |
| LaCreta, F | 1 |
| DeLap, RJ | 1 |
| Grillo-Lopez, AJ | 1 |
| Catalano, R | 1 |
| Comis, RL | 1 |
| Bishop, JF | 1 |
| Raghavan, D | 1 |
| Olver, IN | 1 |
| Reece, P | 1 |
| Morris, R | 1 |
| Friedlander, ML | 1 |
| Fanucchi, MP | 1 |
| Walsh, TD | 1 |
| Fleisher, M | 1 |
| Lokos, G | 1 |
| Williams, L | 1 |
| Cassidy, C | 1 |
| Vidal, P | 1 |
| Chou, TC | 1 |
| Niedzwiecki, D | 1 |
| Young, CW | 1 |
| Grem, JL | 1 |
| Ellenberg, SS | 1 |
| King, SA | 1 |
| Shoemaker, DD | 1 |
3 trials available for trimetrexate and Thrombopenia
| Article | Year |
|---|---|
Trimetrexate in advanced hormone-refractory prostate cancer. An ECOG phase II trial.
Topics: Aged; Anemia; Humans; Leukopenia; Male; Middle Aged; Prostatic Neoplasms; Thrombocytopenia; Treatmen | 1994 |
Phase I trial of trimetrexate in pediatric solid tumors: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Brain Neoplasms; Carcinoma, Renal Cell; Child; Child, Preschool; Female; Follow-U | 1993 |
High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection?
Topics: Adolescent; Adult; Antidotes; Antimetabolites, Antineoplastic; Child; Child, Preschool; Drug Interac | 1998 |
4 other studies available for trimetrexate and Thrombopenia
| Article | Year |
|---|---|
Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Chro | 1989 |
A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion.
Topics: Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Evaluation; Female; Humans; I | 1989 |
Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Chromatography, High Pressure Liquid; Deoxyuridine; Drug E | 1987 |
Correlates of severe or life-threatening toxic effects from trimetrexate.
Topics: Adult; Antineoplastic Agents; Drug Evaluation; Folic Acid Antagonists; Humans; Quinazolines; Serum A | 1988 |